William Hodder has over 28 years of broad Pharmaceutical and Biotechnology industry experience including business development, corporate and product marketing, sales, fundraising and product development. Mr. Hodder is currently SVP, Corporate Development at Protagonist Therapeutics responsible for all licensing and fundraising activities. Previously Mr. Hodder was Founder and CEO of Trenovus, Inc. a start‐up biotechnology company focused on developing novel inhibitors of heterotopic ossification present in a number of conditions including Ankylosing Spondylitis and Fibrodysplasia Ossificans Progressiva. Prior to Trenovus, Mr. Hodder was Vice President, Business Development of FibroGen, Inc. Mr. Hodder was responsible for all licensing and M&A activity at FibroGen including ongoing partner Alliance Management. Mr. Hodder executed a large number and variety of transactions while at FibroGen including licensing agreements, feasibility agreements, manufacturing agreements, intellectual property in‐licensing agreements, and acquisitions. Most significantly, Mr. Hodder led FibroGen in the historic out‐licensing of HIF prolyl hydroxylase inhibitors for anemia indications to Astellas for the European, South Africa and Middle East territories in February 2006. Deal terms included $300M cash upfront, $50M equity investment and significant development and sales milestones. This transaction was voted most significant partnering deal of 2006 at The Biotech Meeting at Laguna Niguel. Prior to joining FibroGen in 2001, he was at the drug delivery company Aradigm, where he was a Director of Business Development and Marketing from 1997 to 2001. Since 1986, Mr. Hodder has held sales, marketing, and product development positions at Penederm (now Bertek Pharmaceuticals), Ciba Geigy (now Novartis), Bristol‐Myers Squibb Company, and Marion Laboratories (now Sanofi Aventis). Mr. Hodder completed his undergraduate studies at Oakland University with a B.S. in biology and holds an M.B.A. from the University of Chicago Booth School of Business and has been invited to speak at numerous licensing events.